Cargando…

Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak

BACKGROUND: Regdanvimab is a monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a treatment option for patients with mild-to moderate coronavirus disease 2019 (COVID-19). However, there has been limited information on the clinical effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Chan Mi, Park, Sang-Won, Lee, Eunyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259914/ https://www.ncbi.nlm.nih.gov/pubmed/35706081 http://dx.doi.org/10.3947/ic.2022.0011

Ejemplares similares

Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
por: Noh, Hyeong-Jun, et al.
Publicado: (2023)

Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Choi, Seong Jin, et al.
Publicado: (2022)

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
por: Kim, Jin Yong, et al.
Publicado: (2022)

Effectiveness and Safety of Regdanvimab in Patients With Mild-To-Moderate COVID-19: A Retrospective Cohort Study
por: Park, Susin, et al.
Publicado: (2022)

Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022)

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
por: Lee, Shinwon, et al.
Publicado: (2022)

Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Use of the Monoclonal Antibody Regdanvimab to Treat Patients Hospitalized with COVID-19: Real-World Data during the Delta Variant Predominance
por: Kwak, Yee Gyung, et al.
Publicado: (2022)

Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
Publicado: (2023)

Correction to: Regdanvimab: First Approval
por: Syed, Yahiya Y.
Publicado: (2021)

Regdanvimab Treatment of COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
por: Hong, Sun In, et al.
Publicado: (2022)

546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
por: Ison, Michael G, et al.
Publicado: (2021)

Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
por: Kim, Haein, et al.
Publicado: (2023)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
por: Lee, Ji Yeon, et al.
Publicado: (2021)

Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed
por: Lee, Chan Mi, et al.
Publicado: (2022)

Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
por: Fomina, Daria S., et al.
Publicado: (2023)

Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea
por: Lee, Ji Yeon, et al.
Publicado: (2023)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis
por: Yang, Mingyang, et al.
Publicado: (2022)

Clinical Characteristics of COVID-19: Risk Factors for Early Oxygen Requirement after Hospitalization
por: Suh, Hyeon Jeong, et al.
Publicado: (2021)

Nosocomial Outbreak by Delta Variant From a Fully Vaccinated Patient
por: Jung, Jiwon, et al.
Publicado: (2022)

Increasing oxygen requirements and disease severity in pregnant individuals with the SARS-CoV-2 Delta variant
por: Eid, Joe, et al.
Publicado: (2022)

The Impact of Wearing a Mask on Oxygenation and Hemodynamics in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease
por: Kim, Sang-Heon, et al.
Publicado: (2023)

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
por: Marcec, Robert, et al.
Publicado: (2023)

Impact of mild to moderate COPD on feasibility and prognosis in non-small cell lung cancer patients who received chemotherapy
por: Omote, Norihito, et al.
Publicado: (2017)

The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
por: Chae, Ganghee, et al.
Publicado: (2022)

Crucial control measures to contain China's first Delta variant outbreak
por: Luo, Lei, et al.
Publicado: (2022)

An Outbreak of Breakthrough Infections by the SARS-CoV-2 Delta Variant in a Psychiatric Closed Ward
por: Wi, Yu Mi, et al.
Publicado: (2022)

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic
por: Suzuki, Yasuhito, et al.
Publicado: (2022)

Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China
por: Li, Kangguo, et al.
Publicado: (2023)

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19
por: McSweeney, Morgan D., et al.
Publicado: (2022)

Dalbavancin dosage adjustments not required for patients with mild to moderate renal impairment
por: Dowell, J, et al.
Publicado: (2008)

How to deal with the Delta variant this fall
por: Lee, Jong-Koo
Publicado: (2021)

Delta and the Variants
por: Suresh, Mithun R., et al.
Publicado: (2022)

The outbreak of Delta Plus variant: The notorious and novel strain of SARS-CoV-2
por: Richi, Fahmida Tasnim, et al.
Publicado: (2022)

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together
por: Zhang, Lin, et al.
Publicado: (2021)

Outcomes of Infants with Mild Hypoxic Ischemic Encephalopathy Who Did Not Receive Therapeutic Hypothermia
por: Reiss, Jonathan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bgv72277tritrbgndnrklphe49